Physician

Mark C Cascione, M.D.

According to 2025 Medicare claims, Mark Cascione, M.D. (NPI: 1447249115) practices neurology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is NEUROSCIENCE CONSULTANTS LLP (NPI: 1346217452; TIN: 542107535) and primary practice location at 33609-4083.

Cascione's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 156 traditional Medicare patients, billed 51,905 HCPCS/CPT codes, and received $2,216,776 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,619 prescription claims across 220 beneficiaries totaling $2,926,375 in drug costs, led by Zeposia (Ozanimod Hydrochloride). 2018 DME data shows 31 claims. Open Payments data shows 457 records totaling $2,330,275. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $45,381 to $2,216,776. In contrast, Part D prescription costs have declined steadily, from $5,599,378 to $2,926,375. For DME billing, this smaller-volume category moved sharply higher in recent years, from $42,454 to $27,840.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	235	1,832	$45,381
2016	243	1,682	$47,610
2017	168	1,312	$30,936
2018	156	977	$24,674
2019	168	10,128	$400,101
2020	152	34,207	$1,536,269
2021	159	42,522	$1,582,344
2022	154	47,195	$1,851,080
2023	153	50,927	$2,099,271
2024	156	51,905	$2,216,776

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	220	3,080	$5,599,378
2016	220	3,012	$5,761,401
2017	207	2,938	$5,556,498
2018	203	2,842	$5,103,494
2019	196	2,744	$4,919,416
2020	194	2,756	$4,197,825
2021	190	2,681	$3,369,087
2022	202	2,775	$3,157,497
2023	219	2,820	$3,197,950
2024	220	2,619	$2,926,375

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	12	$520
2017	N/R	N/R	N/R
2018	N/R	31	$1,941
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	128	208	$124
96413	Administration of chemotherapy into vein, 1 hour or less	51	123	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	43	54	$81
J2350	Injection, ocrelizumab, 1 mg	38	39,600	$46
96415	Administration of chemotherapy into vein, each additional hour	43	97	$20

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Zeposia	Ozanimod Hydrochloride	49	1,807	$520,637
Kesimpta Pen	Ofatumumab	38	1,102	$364,723
Aubagio	Teriflunomide	31	930	$275,214
Rebif Rebidose	Interferon Beta-1a/Albumin	16	616	$235,453
Copaxone	Glatiramer Acetate	23	644	$130,873

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	405	$132,504	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	52	$2,197,770	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark C. Cascione, M.D.?

Tedicare shows public-source Medicare data for Mark C. Cascione, M.D. (NPI 1447249115), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark C. Cascione, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark C. Cascione, M.D.?

Mark C. Cascione, M.D. is linked to NEUROSCIENCE CONSULTANTS LLP (billing NPI 1346217452) in the available physician profile data.

Does Mark C. Cascione, M.D. have Open Payments data?

Mark C. Cascione, M.D. has 457 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.